PURPOSE: Breast cancer resistance protein (BCRP/ABCG2), an ATP binding cassette half-transporter, confers resistance to mitoxantrone, doxorubicin, and topoisomerase I inhibitors of irinotecan and topotecan. Recently, we reported that BCRP efficiently transported SN-38 (the active metabolite of irinotecan) with a high affinity in lung cancer cells in vitro (K. Nakatomi et al., Biochem. Biophys. Res. Commun., 288: 827-832, 2001). The aim of this study is to explore the role of BCRP in the drug resistance of lung cancer. EXPERIMENTAL DESIGN: The BCRP mRNA expression in lung cancer cells and 23 untreated non-small cell lung cancer (NSCLC) tissues was quantitated by real-time reverse transcription-PCR. To evaluate the drug-efflux function of BCRP, the intracellular topotecan accumulation and drug sensitivity were measured in lung cancer cells with various levels of the BCRP mRNA expression by flow cytometric and tetrazolium dye assay, respectively. RESULTS: The levels of BCRP mRNA expression in the cell lines were significantly correlated with the BCRP function and the sensitivity to SN-38 and topotecan. In NSCLC tissues, the BCRP mRNA expression levels were widely dispersed. Five (22%) of 23 tissues expressed higher levels of the BCRP mRNA than that in NCI-H441 cells with active BCRP function conferring high resistance to topotecan in vitro. CONCLUSIONS: Some NSCLC tissues expressed sufficient levels of the BCRP mRNA to confer drug resistance in vitro.
PURPOSE:Breast cancer resistance protein (BCRP/ABCG2), an ATP binding cassette half-transporter, confers resistance to mitoxantrone, doxorubicin, and topoisomerase I inhibitors of irinotecan and topotecan. Recently, we reported that BCRP efficiently transported SN-38 (the active metabolite of irinotecan) with a high affinity in lung cancer cells in vitro (K. Nakatomi et al., Biochem. Biophys. Res. Commun., 288: 827-832, 2001). The aim of this study is to explore the role of BCRP in the drug resistance of lung cancer. EXPERIMENTAL DESIGN: The BCRP mRNA expression in lung cancer cells and 23 untreated non-small cell lung cancer (NSCLC) tissues was quantitated by real-time reverse transcription-PCR. To evaluate the drug-efflux function of BCRP, the intracellular topotecan accumulation and drug sensitivity were measured in lung cancer cells with various levels of the BCRP mRNA expression by flow cytometric and tetrazolium dye assay, respectively. RESULTS: The levels of BCRP mRNA expression in the cell lines were significantly correlated with the BCRP function and the sensitivity to SN-38 and topotecan. In NSCLC tissues, the BCRP mRNA expression levels were widely dispersed. Five (22%) of 23 tissues expressed higher levels of the BCRP mRNA than that in NCI-H441 cells with active BCRP function conferring high resistance to topotecan in vitro. CONCLUSIONS: Some NSCLC tissues expressed sufficient levels of the BCRP mRNA to confer drug resistance in vitro.
Authors: Joel G Turner; Jana L Gump; Chunchun Zhang; James M Cook; Douglas Marchion; Lori Hazlehurst; Pamela Munster; Michael J Schell; William S Dalton; Daniel M Sullivan Journal: Blood Date: 2006-08-17 Impact factor: 22.113
Authors: S Faraj; M Bahri; S Fougeray; A El Roz; J Fleurence; J Véziers; M D Leclair; E Thébaud; F Paris; S Birklé Journal: Oncoimmunology Date: 2017-09-21 Impact factor: 8.110
Authors: C Hirschmann-Jax; A E Foster; G G Wulf; J G Nuchtern; T W Jax; U Gobel; M A Goodell; M K Brenner Journal: Proc Natl Acad Sci U S A Date: 2004-09-20 Impact factor: 11.205
Authors: Gail M Seigel; Abigail S Hackam; Arupa Ganguly; Lorrie M Mandell; Federico Gonzalez-Fernandez Journal: Mol Vis Date: 2007-06-08 Impact factor: 2.367